Who Supplies Plasma to India from MACEDONIA,THE FORMER YUGOSLAV REPUBLIC OF

To import finished pharmaceutical formulations containing plasma into India, the importing entity must obtain an Import Registration Certificate and an Import License from the Central Drugs Standard Control Organization (CDSCO). The application process involves submitting detailed product information, manufacturing licenses, and certificates of analysis. The registration certificate is valid for three years and is renewable. The Import License is issued after verifying compliance with the Drugs and Cosmetics Act, 1940, and associated rules. The timeline for obtaining these approvals can vary, but it typically ranges from several months to a year, depending on the completeness of the application and the regulatory workload.

Imported pharmaceutical formulations containing plasma must undergo quality testing at CDSCO-approved laboratories. This includes batch-wise testing, where samples from each batch are analyzed to ensure they meet Indian Pharmacopoeia standards. The Certificate of Analysis (CoA) from the exporting country must accompany the shipment. Stability data, particularly for ICH Zone IV conditions, is required to demonstrate the product's shelf-life under Indian climatic conditions. Port inspection by customs drug inspectors is mandatory to verify compliance with regulatory standards.

Between 2024 and 2026, the CDSCO has implemented stricter regulations for importing pharmaceutical products, including formulations containing plasma. These changes aim to enhance drug safety and efficacy by ensuring that imported products meet Indian standards. The introduction of the Production Linked Incentive (PLI) scheme has also impacted the import landscape, encouraging domestic manufacturing and potentially reducing reliance on imports. Bilateral agreements between India and Macedonia The Former Yugoslav Republic Of have been explored to facilitate smoother trade, but as of now, no specific agreements have been finalized.

India imports finished pharmaceutical formulations containing plasma to meet the demand for specialized treatments not available domestically. These include patented or branded formulations and specific dosage forms that are not manufactured within the country. The market size for such imports is significant, with India's total plasma formulation export market valued at $2.8 million across 215 exporters to 90 countries. This indicates a substantial demand for plasma-based formulations in India.

The Basic Customs Duty (BCD) for HS Code 30029010, which covers human blood and related products, is 10%. An Integrated Goods and Services Tax (IGST) of 0% applies, and a Social Welfare Surcharge (SWS) of 10% is levied on the BCD. Therefore, the total landed duty is calculated as follows:

• BCD: 10%
• SWS: 10% of BCD = 1%
• Total Duty: 10% + 1% = 11%

This structure is subject to change based on government policies and trade agreements.

India sources finished pharmaceutical formulations containing plasma from Macedonia The Former Yugoslav Republic Of due to the availability of specialized formulations and competitive pricing. Macedonia The Former Yugoslav Republic Of's share in India's plasma formulation import market is currently minimal, with only one shipment valued at $794. Other major suppliers include countries like China, Germany, and the United States, which have a more established presence in the Indian market.

India imports finished pharmaceutical formulations containing plasma from Macedonia The Former Yugoslav Republic Of due to the availability of specialized formulations not produced domestically. These may include patented or branded formulations and specific dosage forms that cater to niche medical needs. The competitive pricing and favorable exchange rates also make imports from Macedonia The Former Yugoslav Republic Of attractive.

Compared to other origins like China, Germany, and the United States, Macedonia The Former Yugoslav Republic Of offers competitive pricing and specialized formulations. However, the limited shipping infrastructure and higher transit times can be a disadvantage. Regulatory compliance and quality standards are comparable, but the lack of established trade agreements may pose challenges.

Risks include single-source dependency, currency fluctuations, regulatory changes, quality control issues, and potential shipping disruptions. Past shortages have been minimal, but the underdeveloped trade corridor may pose future challenges.

1. 1Dual-Sourcing: Engage multiple suppliers to mitigate risks associated with single-source dependency.
2. 2Inventory Planning: Maintain adequate stock levels to buffer against potential supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC) to secure transactions.
4. 4Supplier Qualification: Conduct thorough due diligence to ensure compliance with Indian regulatory standards.
5. 5Regulatory Monitoring: Stay updated on changes in import policies and tariffs to adjust procurement strategies accordingly.

1. 1DGFT Importer Exporter Code (IEC): Obtain an IEC from the Directorate General of Foreign Trade.
2. 2CDSCO Registration: Register the manufacturing premises and products with CDSCO.
3. 3Import License: Apply for an Import License under Form 10.
4. 4No Objection Certificate (NOC): If applicable, obtain an NOC from the Ministry of Health and Family Welfare.
5. 5Customs Broker: Engage a licensed Customs House Agent for clearance procedures.
6. 6Advance Ruling: Seek an